Pfizer administered one-third the dose of older groups to children 5 to 11 and found they developed the same levels of antibodies as teens and young adults.
German health officials believe that mixing vaccines will help boost vaccine effectiveness in the face of new variants, such as the Delta variant.
Ugur Sahin said his German pharmaceutical company, along with U.S.-based Pfizer, have already delivered vaccines to over 90 countries.
Ugur Sahin, BioNTech's chief executive, said Wednesday that the vaccine his company created with Pfizer will likely require a third booster shot due to data showing a weaker immune response over time in people who received the vaccine.
On Wednesday, American pharmaceutical giant Pfizer announced that its COVID-19 vaccine demonstrated 100 percent efficacy against COVID-19 in a trial involving 12- to 15-0year-olds.
Johnson & Johnson say their vaccine is 66 percent effective overall in preventing moderate to severe COVID-19.
Moderna is developing a version that could be used as a booster shot against the South Africa variant of the virus, as its vaccine was slightly less effective against it.
The study took place in Israel, which is currently leading the world in terms of vaccinating its population.
Maximum protection from the Pfizer-BioNtech vaccine—as well as long-lasting immunity—is only reached seven or more days after the second dose.
But such incident are rare and experts say the benefits of getting the vaccine far outweigh the risks.
Over 30,000 people in the city have had the Pfizer vaccine without experiencing a reaction, according to officials.
Vaccine providers should observe people with a history of anaphylaxis—a severe, potentially life-threatening allergic reaction—due to any cause for 30 minutes after the individual receives the shot.
Experts say anyone with common allergies to medications, foods, inhalants, insects and latex are unlikely to suffer a life-threatening allergic reaction as a result of the Pfizer vaccine.
About 2.9 million doses of the Pfizer/BioNTech coronavirus vaccine will be distributed across the country this week.
The Microsoft co-founder said German scientists and foreign efforts helped create the record-setting vaccines now being rolled out to Americans.
The head of the National Institute of Allergy and Infectious Diseases said it will take a while to achieve herd immunity if a substantial proportion of the population is not vaccinated.
The company has entered into agreements to supply other countries since it reported promising results for its vaccine contender, Scott Gottlieb, the head of the Food and Drug Administration (FDA) said.
Shakespeare, who shares his name with the famous English playwright, has made history by becoming one of the first people to have the shot outside of clinical trials.
Margaret Keenan said being the first person in the U.K. to get a COVID shot outside a clinical trial was "the best early birthday present I could wish for."
Experts told Newsweek the potential harms caused by catching COVID are far worse than those associated with getting a shot.
"The speed of development for this and other vaccine candidates is testament to an extraordinary, collaborative, global research effort," said Charlie Weller from the Wellcome Trust.
The U.K.'s health secretary said the country will be ready to start vaccinating people from early next week.
The move comes after Pfizer-BioNTech claimed their vaccine is 95 percent effective in preventing COVID.
Promising coronavirus vaccine candidates have surfaced this month as the virus continues to surge across the U.S. Behind the scenes, distribution deals have already been made.
Uğur Şahin believes the experimental vaccine, said to be 90 percent effective, will end the COVID-19 pandemic.
"The full data set on which the claim is based has not yet been released and so we don't know exactly what has been found," one immunologist said.
Pfizer said no serious safety concerns have been observed so far.
"The short, less than four-month timeframe in which we've been able to move from pre-clinical studies to human testing is extraordinary," Albert Bourla, chairman and CEO of Pfizer, said.